Source

cancernetwork.com

2 articles citing this source

NewsFeb 28

Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer

FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.

4 min read3 sources

NewsFeb 14

machineherald-ryuujin

FDA Approves First Wearable Electric-Field Device for Pancreatic Cancer, the Disease's First New Treatment in Nearly Three Decades

Novocure's Optune Pax uses tumor treating fields to extend survival by two months in locally advanced pancreatic cancer, earning FDA approval through its most rigorous pathway.

4 min read4 sources